DEF: Precision Optics Sets 2025 Annual Meeting Agenda

Precision Optics Corporation, Inc. announces its 2025 Annual Meeting of Shareholders to vote on director elections, executive compensation, and auditor ratification, alongside key governance updates.

Summary

• The 2025 Annual Meeting of Shareholders will be held on Thursday, March 19, 2026, at 10 a.m. EDT at the Company's corporate headquarters in Littleton, MA.
• Shareholders will vote on the election of five directors: Peter H. Woodward, Andrew J. Miclot, Buell G. Duncan, Joseph P. Pellegrino, Jr., and Joseph N. Forkey.
• An advisory vote will be held to approve the compensation paid to Named Executive Officers for the fiscal year ended June 30, 2025.
• Shareholders will also vote to ratify the appointment of Stowe & Degon, LLC as the independent registered public accounting firm for the fiscal year ending June 30, 2026.
• The record date for shareholders entitled to vote at the meeting is January 28, 2026, with 7,720,229 shares of common stock outstanding.
• The Board of Directors recommends a 'FOR' vote for all three proposals.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with caution due to the significant increase in net losses year-over-year, despite positive governance changes and strategic director appointments. The financial performance overshadows the operational and governance improvements.

Positives

• Appointment of two new independent directors, Buell G. Duncan and Joseph P. Pellegrino, Jr., bringing extensive executive leadership, sales, marketing, strategic, operational, and financial experience from medical device and technology industries.
• The Board believes its structure, with a majority of independent directors (4 out of 5), serves the company well.
• Adoption of a Clawback Policy, effective October 2, 2023, to ensure accountability and reinforce performance-based compensation.
• Implementation of an Insider Trading Policy and a Hedging and Pledging Policy to align management and director interests with long-term shareholder value.
• The Audit Committee and Compensation Committee are established and functioning with independent directors, enhancing oversight.

Negatives

• A significant net loss of $5,780,246 was reported for fiscal year 2025, which is substantially worse than the $2,951,377 loss in 2024 and $144,613 loss in 2023.
• Mahesh Lawande, the former Chief Operating Officer, forfeited 40,000 stock options due to the termination of his employment effective October 31, 2025.
• No employer profit sharing or matching contributions were made to the 401(k) plan in fiscal years 2025 and 2024.
• One delinquent Section 16(a) report was noted for Wayne M. Coll, filed on January 5, 2026, for a report due on April 2, 2025.

Risks

• The company's Insider Trading Policy and Hedging and Pledging Policy are designed to mitigate risks associated with improper conduct and misalignment of interests, implying these are potential risks if not managed.
• Risk of not attracting and retaining highly qualified individuals if compensation is not competitive.
• Risk of not achieving corporate strategies and business objectives if executive compensation is not aligned with performance.
• Risk of financial restatement triggering the clawback policy for executive compensation.

Future Outlook

The Board of Directors takes shareholder views seriously and will consider the advisory vote on executive compensation in future decisions. The company's compensation programs are designed to reward and motivate employees to continue to grow the Company. The Board intends to maintain its current leadership structure, believing it serves the company well, as appropriate and practicable in the future.

Management Comments

• "The Board believes that the nominees knowledge, skills, and abilities will positively contribute to the function of the Board as a whole."
• "Precision Optics has designed its compensation programs to reward and motivate employees to continue to grow the Company."
• "The Board of Directors takes shareholder views seriously and will take into account the advisory vote in future executive compensation decisions."
• "We believe in the power of open disclosure and know the only way to build and strengthen our reputation and our Company is through honesty and trust."

Industry Context

StockSavvy.ai notes that the appointment of directors with extensive experience in the medical device and B2B technology sectors aligns with a broader industry trend of companies seeking specialized expertise to navigate complex markets and drive innovation. The focus on executive compensation and corporate governance reflects increasing investor scrutiny across all industries, particularly for smaller reporting companies.

Comparison to Industry Standards

• The net loss of $5.78 million for FY2025 is a significant concern, especially when compared to the generally profitable landscape of established medical device companies like Medtronic or Johnson & Johnson, which typically report substantial net income.
• The executive compensation structure, including base salary, stock options, and performance bonuses, is a common practice in the medical device and technology sectors, similar to companies like Inari Medical or Shockwave Medical, aiming to align executive incentives with long-term shareholder value. However, the magnitude of the net loss raises questions about the effectiveness of this alignment in the short term.
• The appointment of directors with backgrounds from companies like LeMaitre Vascular, Inc. (a Nasdaq-listed medical device company) and IBM (global technology) suggests an effort to bring in seasoned leadership comparable to larger industry players, enhancing governance and strategic direction.

Management Changes

Corporate Governance

Related Party Transactions

• In connection with a registered direct offering that closed on February 21, 2025, the Company sold 102,500 shares of Common Stock to MHW Partners, LP, a limited partnership of which Mr. Woodward (Chairman of the Board) is the general partner. The Board reviewed and approved this transaction, with Mr. Woodward abstaining from the vote.

Stakeholder Impact

• Shareholders will vote on key governance matters (directors, executive compensation, auditor) and have experienced dilution from equity incentive plan amendments and a direct offering. They are significantly impacted by the increasing net losses.
• Employees benefit from equity incentive plans and compensation programs designed to attract and retain talent.
• Management's compensation is tied to performance, with new clawback policies for accountability. A new COO has been appointed.

Next Steps

• Shareholders are to vote on director elections, executive compensation, and auditor ratification at the 2025 Annual Meeting on March 19, 2026.
• The Board will review its future selection of the independent registered public accounting firm if ratification is not obtained.
• The Compensation Committee will consider the outcome of the Say-on-Pay vote when designing future executive compensation programs.
• Shareholders can submit proposals for the 2026 Annual Meeting by October 5, 2026.

Key Dates

Recommendation

While the company has made positive strides in corporate governance by appointing experienced independent directors and implementing robust policies like clawbacks and insider trading rules, the significant and increasing net losses for fiscal year 2025 are a major concern. The capital raise through a direct offering, while providing funds, also indicates a need for capital and results in dilution. The stock options forfeiture by a former COO also points to potential operational instability. Given the mixed signals of improved governance but deteriorating financial performance, a 'Hold' recommendation is appropriate as investors should monitor future financial results and the impact of new management and board members before making further investment decisions.

Keywords

Precision Optics, SEC filing, DEF 14A, proxy statement, corporate governance, director election, executive compensation, auditor ratification, stock options, net loss, medical device, optical systems, financial reporting, shareholder meeting